Maxim Reiterates ‘Buy’ On Inovio Pharmaceuticals, Adjusts Price Target
In a report published today, Maxim analyst Jason Kolbert reiterated a Buy rating on Inovio Pharmaceuticals, Inc. (INO) with an adjusted price target of $18.00 (from 6.00) following a reverse stock split.
Kolbert noted, “We have recently adjusted our model for the 4:1 reverse stock split which establishes a new price target of $18.00 per share. Our price target assumes a positive outcome of the current phase II trial (HPV-003). Risk adverse investors should be aware we can-not predict the outcome of a binary event”.
According to TipRanks, which measures analysts and bloggers success rate based on how their calls perform, analyst Jason Kolbert currently has a one-year average return of 8.8% and a 54% success rate. He is ranked #518 out of 3112 analysts.